Temporal associations of plasma levels of the secreted phospholipase A2 family and mortality in severe COVID-19

Eur J Immunol. 2024 Jun;54(6):e2350721. doi: 10.1002/eji.202350721. Epub 2024 Apr 23.

Abstract

Previous research suggests that group IIA-secreted phospholipase A2 (sPLA2-IIA) plays a role in and predicts lethal COVID-19 disease. The current study reanalyzed a longitudinal proteomic data set to determine the temporal relationship between levels of several members of a family of sPLA2 isoforms and the severity of COVID-19 in 214 ICU patients. The levels of six secreted PLA2 isoforms, sPLA2-IIA, sPLA2-V, sPLA2-X, sPLA2-IB, sPLA2-IIC, and sPLA2-XVI, increased over the first 7 ICU days in those who succumbed to the disease but attenuated over the same time period in survivors. In contrast, a reversed pattern in sPLA2-IID and sPLA2-XIIB levels over 7 days suggests a protective role of these two isoforms. Furthermore, decision tree models demonstrated that sPLA2-IIA outperformed top-ranked cytokines and chemokines as a predictor of patient outcome. Taken together, proteomic analysis revealed temporal sPLA2 patterns that reflect the critical roles of sPLA2 isoforms in severe COVID-19 disease.

Keywords: COVID‐19; Proteomics; sPLA2.

MeSH terms

  • Adult
  • Aged
  • COVID-19* / blood
  • COVID-19* / mortality
  • Cytokines / blood
  • Female
  • Group II Phospholipases A2 / blood
  • Humans
  • Male
  • Middle Aged
  • Phospholipases A2, Secretory / blood
  • Protein Isoforms / blood
  • Proteomics / methods
  • SARS-CoV-2*
  • Severity of Illness Index

Substances

  • Phospholipases A2, Secretory
  • Group II Phospholipases A2
  • Protein Isoforms
  • Cytokines